NASDAQ:CLVS Clovis Oncology - CLVS Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clovis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$0.08▼$0.1050-Day Range$0.08▼$1.0952-Week Range$0.08▼$3.32Volume1.16 million shsAverage Volume8.88 million shsMarket Capitalization$11.60 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Clovis Oncology MarketRank™ ForecastAnalyst RatingHold1.50 Rating ScoreUpside/Downside6,150.0% Upside$5.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.68) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 starsMedical Sector908th out of 1,026 stocksPharmaceutical Preparations Industry445th out of 504 stocks 2.8 Analyst's Opinion Consensus RatingClovis Oncology has received a consensus rating of Hold. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Clovis Oncology has a forecasted upside of 6,150.0% from its current price of $0.08.Amount of Analyst CoverageClovis Oncology has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CLVS. Previous Next 0.0 Dividend Strength Dividend YieldClovis Oncology does not currently pay a dividend.Dividend GrowthClovis Oncology does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreClovis Oncology has received a 69.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Clovis Oncology is -1.33. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for CLVS on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Clovis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -77% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clovis Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of Clovis Oncology is held by insiders.Percentage Held by InstitutionsOnly 24.53% of the stock of Clovis Oncology is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clovis Oncology are expected to grow in the coming year, from ($1.68) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clovis Oncology is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clovis Oncology is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Clovis Oncology (NASDAQ:CLVS) StockClovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Read More Receive CLVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CLVS Stock News HeadlinesJanuary 30, 2023 | reuters.comCLVS.OJanuary 18, 2023 | seekingalpha.comCLVSQ Clovis Oncology, Inc.February 9, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 13, 2023 | forbes.comClovis OncologyJanuary 3, 2023 | wsj.comFirm Retention Summary: Clovis Oncology Inc.December 12, 2022 | reuters.comCancer drugmaker Clovis files for bankruptcy, hit by falling salesDecember 12, 2022 | benzinga.comThinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?December 12, 2022 | bizjournals.comBoulder drugmaker Clovis Oncology files for bankruptcyFebruary 9, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.December 12, 2022 | finance.yahoo.comClovis Plans to Sell Cancer Drug to Novartis in Bankruptcy DealDecember 12, 2022 | finance.yahoo.comClovis (CLVS) Files for Bankruptcy Amid Lack of Financial AidDecember 12, 2022 | finance.yahoo.comClovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to NovartisDecember 12, 2022 | benzinga.comCancer Focused Clovis Oncology Files For BankruptcyDecember 12, 2022 | seekingalpha.comClovis stock slumps amid Chapter 11 filing, to sell FAP-2286 to Novartis for $50M upfrontDecember 12, 2022 | marketwatch.comClovis Oncology Shares Fall Premarket After Bankruptcy Filing >CLVSDecember 12, 2022 | finance.yahoo.comClovis Oncology stock slides 10% premarket after company files for bankruptcyDecember 12, 2022 | finance.yahoo.comClovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286December 12, 2022 | finance.yahoo.comU.S. drugmaker Clovis files for Chapter 11 bankruptcyDecember 12, 2022 | finance.yahoo.comUPDATE 1-Cancer drugmaker Clovis files for bankruptcy, hit by falling salesNovember 25, 2022 | finance.yahoo.comClovis (CLVS) Stock Down 50% in the Past 6 Months: Here's WhyNovember 21, 2022 | finance.yahoo.comDown 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)November 11, 2022 | finance.yahoo.comClovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 9, 2022 | finance.yahoo.comClovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing LoomsNovember 9, 2022 | finance.yahoo.comClovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023November 9, 2022 | reuters.comClovis Oncology says could file for bankruptcy in 'very near term'November 9, 2022 | seekingalpha.comClovis Oncology falls 55% on bankruptcy concernsNovember 9, 2022 | nasdaq.comClovis Oncology Tanks On Possible Bankruptcy FilingSee More Headlines Receive CLVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CLVS Company Calendar Last Earnings11/03/2021Today2/09/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLVS CUSIP18946410 CIK1466301 Webwww.clovisoncology.com Phone303-625-5000Fax303-245-0360EmployeesN/AYear Founded2009Price Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+6,150.0%Consensus RatingHold Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-264,520,000.00 Net Margins-189.37% Pretax Margin-189.68% Return on EquityN/A Return on Assets-57.78% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$148.76 million Price / Sales0.08 Cash FlowN/A Price / Cash FlowN/A Book Value($2.15) per share Price / Book-0.04Miscellaneous Outstanding Shares144,955,000Free Float138,577,000Market Cap$11.60 million OptionableOptionable Beta0.24 Social Links Key ExecutivesMr. Patrick J. Mahaffy MA (Age 55)Co-Founder, Chief Exec. Officer, Pres and Exec. Director Dr. Gillian C. Ivers-Read BSc (Age 64)Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations Mr. Daniel W. Muehl CPA (Age 54)Sr. VP of Fin. and Principal Financial & Accounting Officer Dr. Lindsey Rolfe BSc (Age 50)MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance Mr. Corwin Dale Hooks (Age 51)Chief Commercial Officer and Sr. VP Key CompetitorsCatalyst BiosciencesNASDAQ:CBIORegulus TherapeuticsNASDAQ:RGLSMolecular TemplatesNASDAQ:MTEMAileron TherapeuticsNASDAQ:ALRNImunonNASDAQ:IMNNView All CompetitorsInsiders & InstitutionsCutler Group LLC CASold 17,800 shares on 2/7/2023Ownership: 0.000%Wolverine Asset Management LLCSold 100,100 shares on 2/1/2023Ownership: 0.000%Bank of Montreal CanSold 100,400 shares on 2/1/2023Ownership: 0.000%Jane Street Group LLCSold 258,600 shares on 11/16/2022Ownership: 0.000%Bank of New York Mellon CorpBought 27,477 shares on 11/15/2022Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions CLVS Stock - Frequently Asked Questions Should I buy or sell Clovis Oncology stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares. View CLVS analyst ratings or view top-rated stocks. What is Clovis Oncology's stock price forecast for 2023? 2 brokerages have issued 12-month price targets for Clovis Oncology's shares. Their CLVS share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 6,150.0% from the stock's current price. View analysts price targets for CLVS or view top-rated stocks among Wall Street analysts. When is Clovis Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our CLVS earnings forecast. How were Clovis Oncology's earnings last quarter? Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to the consensus estimate of $38.73 million. During the same quarter in the prior year, the company earned ($0.89) EPS. What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO? 12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Clovis Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). What is Clovis Oncology's stock symbol? Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS." Who are Clovis Oncology's major shareholders? Clovis Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cutler Group LLC CA (0.00%), Bank of Montreal Can (0.00%), Wolverine Asset Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding. View institutional ownership trends. What is Clovis Oncology's stock price today? One share of CLVS stock can currently be purchased for approximately $0.08. How much money does Clovis Oncology make? Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $11.60 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. How can I contact Clovis Oncology? Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360. This page (NASDAQ:CLVS) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.